{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:06:58Z","timestamp":1779188818081,"version":"3.51.4"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR074997"],"award-info":[{"award-number":["AR074997"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cell & Developmental Biology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.semcdb.2019.12.007","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:28:02Z","timestamp":1576492082000},"page":"146-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies"],"prefix":"10.1016","volume":"101","author":[{"given":"Yoshihide","family":"Asano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcdb.2019.12.007_bib0005","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/EBC20190001","article-title":"Exploring the extracellular matrix in health and disease using proteomics","volume":"63","author":"Taha","year":"2019","journal-title":"Essays Biochem."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2017.09.011","article-title":"Endogenous ligands of TLR4 promote unresolving tissue fibrosis: implications for systemic sclerosis and its targeted therapy","volume":"195","author":"Bhattacharyya","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/iub.493","article-title":"Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models","volume":"63","author":"White","year":"2011","journal-title":"IUBMB Life"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/19336918.2014.987587","article-title":"Tenascin-C: form versus function","volume":"9","author":"Giblin","year":"2015","journal-title":"Cell Adh. Migr."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0035","first-page":"3","article-title":"TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung","author":"Bhattacharyya","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0040","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","article-title":"Tenascin-C drives persistence of organ fibrosis","volume":"7","author":"Bhattacharyya","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008264","article-title":"FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling","volume":"6","author":"Bhattacharyya","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0050","article-title":"The ECM-protein knowledge database","author":"Shao","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","article-title":"Fibrosis--a lethal component of systemic sclerosis","volume":"10","author":"Ho","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI93555","article-title":"Fibroblast heterogeneity: implications for human disease","volume":"128","author":"Lynch","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI130239","article-title":"Dermal adipose tissue has high plasticity and undergoes reversible dedifferentiation in mice","author":"Zhang","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0080","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.38990","article-title":"Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors","volume":"67","author":"Marangoni","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrrheum.2016.223","article-title":"Systemic sclerosis in 2016: dermal white adipose tissue implicated in SSc pathogenesis","volume":"13","author":"Varga","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0090","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.matbio.2018.01.019","article-title":"The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication","volume":"68\u201369","author":"Pakshir","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature24676","article-title":"IL-11 is a crucial determinant of cardiovascular fibrosis","volume":"552","author":"Schafer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/08916939409010671","article-title":"Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis","volume":"17","author":"Feghali","year":"1994","journal-title":"Autoimmunity"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0110","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0115","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3389\/fimmu.2019.01093","article-title":"Coordination of immune-stroma crosstalk by IL-6 family cytokines","volume":"10","author":"West","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0125","article-title":"Targeting metabolic dysregulation for fibrosis therapy","author":"Zhao","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-018-0710-z","article-title":"Matrix stiffness: the conductor of organ fibrosis","volume":"20","author":"Santos","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0135","first-page":"131","article-title":"RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation","author":"Oh","year":"2018","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0140","first-page":"11","article-title":"Selective YAP\/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis","author":"Haak","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta--at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/wrr.12398","article-title":"Transforming growth factor beta (TGF-beta) isoforms in wound healing and fibrosis","volume":"24","author":"Lichtman","year":"2016","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0160","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/art.39242","article-title":"Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor beta","volume":"67","author":"Piera-Velazquez","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0165","first-page":"10","article-title":"TGF-beta1 signaling and tissue fibrosis","author":"Kim","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0170","first-page":"11","article-title":"Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis","author":"Shin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","author":"Distler","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0180","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","article-title":"A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity","volume":"130","author":"Sargent","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0185","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","article-title":"A selective transforming growth factor-beta ligand trap attenuates pulmonary hypertension","volume":"194","author":"Yung","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0190","first-page":"8","article-title":"Regulation of the bioavailability of TGF-beta and TGF-beta-related proteins","author":"Robertson","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0195","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0002-9440(10)63215-4","article-title":"Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts","volume":"164","author":"Asano","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0200","doi-asserted-by":"crossref","first-page":"28597","DOI":"10.1038\/srep28597","article-title":"Metformin is a novel suppressor for transforming growth factor (TGF)-beta1","volume":"6","author":"Xiao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0205","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00060.2014","article-title":"Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription","volume":"307","author":"Tsou","year":"2014","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0210","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0215","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0220","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0225","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187580","article-title":"Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Martyanov","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0240","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","article-title":"Review: frontiers of antifibrotic therapy in systemic sclerosis","volume":"69","author":"Distler","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013778","article-title":"PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-015-0641-2","article-title":"A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-gamma) gene and systemic sclerosis","volume":"17","author":"Marangoni","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0260","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","article-title":"Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension","volume":"76","author":"Avouac","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0265","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","article-title":"Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease","volume":"63","author":"Bogatkevich","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0270","first-page":"2","article-title":"Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis","author":"Shea","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0275","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.39084","article-title":"A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis","volume":"67","author":"Spadoni","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0280","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0285","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0290","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","article-title":"Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis","volume":"72","author":"Beyer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0295","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of beta-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0300","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/art.34444","article-title":"Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis","volume":"64","author":"Horn","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0305","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"Didiasova","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0310","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1756-185X.13247","article-title":"Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Xiao","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0315","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0330","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","article-title":"Role of IL-13 in systemic sclerosis","volume":"56","author":"Fuschiotti","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0335","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0340","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1096\/fj.201600646R","article-title":"Cannabinoids, inflammation, and fibrosis","volume":"30","author":"Zurier","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0345","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0350","doi-asserted-by":"crossref","first-page":"21703","DOI":"10.1038\/srep21703","article-title":"The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-gamma and CB2 pathways","volume":"6","author":"del Rio","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0355","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.matbio.2017.11.010","article-title":"Inflammation and fibrosis","volume":"68\u201369","author":"Mack","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0360","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate immunity in systemic sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0365","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pharmthera.2018.08.003","article-title":"Targeting TLRs and the inflammasome in systemic sclerosis","volume":"192","author":"Henderson","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0370","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-019-0831-z","article-title":"Macrophages in systemic sclerosis: novel insights and therapeutic implications","volume":"21","author":"Toledo","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0380","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","article-title":"A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"67","author":"Rice","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0385","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar3066","article-title":"Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis","volume":"12","author":"Higashi-Kuwata","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0390","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8509583","article-title":"Soluble CD163 as a potential biomarker in systemic sclerosis","volume":"2018","author":"Frantz","year":"2018","journal-title":"Dis. Markers"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0395","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3109\/s10165-012-0813-8","article-title":"Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis","volume":"23","author":"Yukawa","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0400","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.30190","article-title":"Mast cells are a source of transforming growth factor \u03b2 in systemic sclerosis","volume":"63","author":"H\u00fcgle","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0405","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1172\/JCI99088","article-title":"PAI1 mediates fibroblast-mast cell interactions in skin fibrosis","volume":"128","author":"Pincha","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0410","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.4049\/jimmunol.171.9.4830","article-title":"IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells","volume":"171","author":"Kandere-Grzybowska","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0415","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1164\/ajrccm.149.5.8173768","article-title":"Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement","volume":"149","author":"Crestani","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0420","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jdermsci.2017.12.005","article-title":"Systemic sclerosis complicated with localized scleroderma-like lesions induced by Kobner phenomenon","volume":"89","author":"Saigusa","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0425","first-page":"57","article-title":"Ketotifen prevents skin fibrosis in the tight skin mouse","volume":"17","author":"Walker","year":"1990","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0430","first-page":"299","article-title":"Inhibition of fibrosis in TSK mice by blocking mast cell degranulation","volume":"14","author":"Walker","year":"1987","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0435","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0440","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2013.00266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"Wu","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0445","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0450","first-page":"3","article-title":"pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis","author":"Kafaja","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001510","article-title":"TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis","volume":"2","author":"Trujillo","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0460","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0465","first-page":"10","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","author":"Ah Kioon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0470","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0475","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12016-015-8505-8","article-title":"T and NK cell phenotypic abnormalities in systemic sclerosis: a cohort study and a comprehensive literature review","volume":"49","author":"Almeida","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0480","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clim.2016.09.004","article-title":"The magnitude of cytokine production by stimulated CD56(+) cells is associated with early stages of systemic sclerosis","volume":"173","author":"Cossu","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0485","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3389\/fimmu.2018.01665","article-title":"Natural killer cells exhibit a peculiar phenotypic profile in systemic sclerosis and are potent inducers of endothelial microparticles release","volume":"9","author":"Benyamine","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0490","first-page":"283","article-title":"Reduced circulating natural killer T cells and gamma\/delta T cells in patients with systemic sclerosis","volume":"32","author":"Riccieri","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0495","first-page":"10","article-title":"Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis","author":"Maugeri","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0500","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1073\/pnas.1315854111","article-title":"IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis","volume":"111","author":"Hams","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0505","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.1501491","article-title":"CD4+ group 1 innate lymphoid cells (ILC) form a functionally distinct ILC subset that is increased in systemic sclerosis","volume":"196","author":"Roan","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0510","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/annrheumdis-2015-207388","article-title":"Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis","volume":"75","author":"Wohlfahrt","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0515","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.autrev.2017.10.015","article-title":"Altered B lymphocyte homeostasis and functions in systemic sclerosis","volume":"17","author":"Forestier","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0520","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0525","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0530","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2249.2009.04059.x","article-title":"Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis","volume":"159","author":"Odaka","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0535","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0540","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0545","first-page":"389","article-title":"The role of B cells in systemic sclerosis","volume":"2","author":"Kraaij","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0550","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis-associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","article-title":"Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease","volume":"6","author":"De Santis","year":"2012","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0560","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0565","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0570","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0575","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/1346-8138.13184","article-title":"B lymphocytes in systemic sclerosis: abnormalities and therapeutic targets","volume":"43","author":"Yoshizaki","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0580","first-page":"2056","article-title":"Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF","volume":"34","author":"Matsushita","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0585","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0590","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0595","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0600","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/rheumatology\/keu479","article-title":"Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis","volume":"54","author":"Akamata","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0605","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/bjd.14699","article-title":"A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis","volume":"175","author":"Takahashi","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0610","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.4049\/jimmunol.175.7.4555","article-title":"Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the \u201cscleroderma phenotype\u201d","volume":"175","author":"Zhou","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0615","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2004.02615.x","article-title":"Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis","volume":"138","author":"Nishijima","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0620","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0625","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0630","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0635","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0640","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0645","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","author":"Daoussis","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0650","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0655","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease","author":"Ebata","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0660","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0665","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0670","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2004.027094","article-title":"Early T cell activation in the skin from patients with systemic sclerosis","volume":"64","author":"Kalogerou","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0675","first-page":"275","article-title":"Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis","volume":"33","author":"Matsushita","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0680","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar4430","article-title":"Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction","volume":"16","author":"Yang","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0685","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0690","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","article-title":"Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts","volume":"188","author":"Nakashima","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0695","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.humimm.2014.12.008","article-title":"The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis","volume":"76","author":"Zhou","year":"2015","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0700","article-title":"Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis","author":"Lei","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0705","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1002\/art.34643","article-title":"Potential roles of interleukin-17A in the development of skin fibrosis in mice","volume":"64","author":"Okamoto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0715","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09633.x","article-title":"Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea","volume":"162","author":"Antiga","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0720","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","article-title":"Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions","volume":"71","author":"Mathian","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0725","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","article-title":"Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity","volume":"261","author":"Slobodin","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0730","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116525","article-title":"Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma","volume":"70","author":"Klein","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0735","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2010.06.004","article-title":"Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes","volume":"137","author":"Giovannetti","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0740","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2010.137935","article-title":"The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study","author":"Becker","year":"2011","journal-title":"Ann. Rheum. Dis. Engl."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0745","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0750","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis - results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0755","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2017.12.001","article-title":"Chemokines in systemic sclerosis","volume":"195","author":"King","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0760","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","article-title":"Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development","volume":"9","author":"Castelino","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0765","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0770","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/s10165-012-0795-6","article-title":"Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study","volume":"23","author":"Hasegawa","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0775","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3899\/jrheum.161092","article-title":"Fli1 deficiency induces CXCL6 expression in dermal fibroblasts and endothelial cells, contributing to the development of fibrosis and vasculopathy in systemic sclerosis","volume":"44","author":"Taniguchi","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0780","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/exd.13724","article-title":"CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis","volume":"27","author":"Taniguchi","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0790","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0795","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0800","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/ijd.12839","article-title":"Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis","volume":"55","author":"Xu","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0805","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/art.24688","article-title":"STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis","volume":"60","author":"Dieude","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0810","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0815","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","author":"Wang","year":"2019","journal-title":"J. Scleroderma Relat. Disord."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0820","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0825","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0830","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2013.202","article-title":"Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study","volume":"49","author":"Baraut","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0835","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3389\/fimmu.2018.02013","article-title":"Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges","volume":"9","author":"Peltzer","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0840","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0845","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.leu.2404996","article-title":"Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L","author":"Christopeit","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0850","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/art.30431","article-title":"Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases","volume":"63","author":"Keyszer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0855","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-153-10-201011160-00007","article-title":"Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report","volume":"153","author":"Guiducci","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108765","article-title":"Adipose-derived stem cells: sources, potency, and implications for regenerative therapies","volume":"114","author":"Si","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0865","first-page":"69","article-title":"Adipose-derived cell therapy for hand dysfunction in patients with systemic sclerosis: a randomized, double-bind, placebo-controlled trial","volume":"3","author":"Khanna","year":"2018","journal-title":"J. Scleroderma Relat. Disorders"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0870","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0875","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201004082","article-title":"Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression","volume":"190","author":"Liu","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0880","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.redox.2016.06.005","article-title":"Redox mechanisms in age-related lung fibrosis","volume":"9","author":"Kurundkar","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0885","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0890","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI93563","article-title":"Resolution of organ fibrosis","volume":"128","author":"Jun","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0895","first-page":"9","article-title":"Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis","author":"Lagares","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0900","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.03.016","article-title":"A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD(+) decline","volume":"27","author":"Tarrago","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0910","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0915","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in Immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0920","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1186\/ar4070","article-title":"The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy","volume":"14","author":"Fang","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0925","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","article-title":"Metformin and autoimmunity: a \u201cNew deal\u201d of an old drug","volume":"9","author":"Ursini","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0930","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/s41467-019-10839-0","article-title":"Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis","volume":"10","author":"Kheirollahi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0935","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41591-018-0087-6","article-title":"Metformin reverses established lung fibrosis in a bleomycin model","volume":"24","author":"Rangarajan","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0940","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-018-0099-0","article-title":"New insights into the genetics and epigenetics of systemic sclerosis","volume":"14","author":"Angiolilli","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0945","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrm.2016.93","article-title":"Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds","volume":"17","author":"Bonkowski","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0950","doi-asserted-by":"crossref","first-page":"69321","DOI":"10.18632\/oncotarget.12504","article-title":"SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis","volume":"7","author":"Akamata","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0955","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor beta signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0960","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcdb.2019.12.007_bib0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102396","article-title":"Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy","author":"Henry","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0970","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41467-018-04336-z","article-title":"Fibrotic microtissue array to predict anti-fibrosis drug efficacy","volume":"9","author":"Asmani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0975","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd.2016.124","article-title":"Reducing the risk of failure: biomarker-guided trial design","volume":"15","author":"Townsend","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0980","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/acr2.11049","article-title":"Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease","volume":"1","author":"Silver","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0985","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0990","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib0995","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/CS20150697","article-title":"Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis","volume":"130","author":"Evans","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1000","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","article-title":"Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1005","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/ncomms6797","article-title":"Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis","volume":"5","author":"Noda","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1010","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.04.013","article-title":"Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway","volume":"87","author":"Zhu","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1020","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1073\/pnas.1813006116","article-title":"Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma","volume":"116","author":"Tsou","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","article-title":"The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Bergmann","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1030","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.4049\/jimmunol.1200822","article-title":"The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma","volume":"190","author":"Makino","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1035","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10875-013-9896-z","article-title":"MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression","volume":"33","author":"Zhu","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1040","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.27443","article-title":"MicroRNA-29, a key regulator of collagen expression in systemic sclerosis","volume":"62","author":"Maurer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1045","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/rheumatology\/ket254","article-title":"Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor beta","volume":"52","author":"Tanaka","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semcdb.2019.12.007_bib1050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajpath.2012.09.023","article-title":"miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3","volume":"182","author":"Honda","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1055","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.4049\/jimmunol.1100876","article-title":"TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts","volume":"188","author":"Honda","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopha.2016.12.080","article-title":"MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1","volume":"87","author":"Zhou","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13075-017-1331-z","article-title":"Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis","volume":"19","author":"Artlett","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1070","doi-asserted-by":"crossref","first-page":"20314","DOI":"10.1038\/srep20314","article-title":"Targeting miR-155 to treat experimental scleroderma","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","article-title":"miR-155 in the progression of lung fibrosis in systemic sclerosis","volume":"18","author":"Christmann","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/14397595.2014.1001311","article-title":"MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor gamma","volume":"25","author":"Luo","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaut.2017.12.015","article-title":"Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis","volume":"89","author":"Chouri","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/kew336","article-title":"Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression","volume":"56","author":"Nakayama","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semcdb.2019.12.007_bib1095","doi-asserted-by":"crossref","first-page":"25066","DOI":"10.1038\/srep25066","article-title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics","volume":"6","author":"O\u2019Reilly","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdermsci.2016.06.013","article-title":"Altered expression of CD63 and exosomes in scleroderma dermal fibroblasts","volume":"84","author":"Nakamura","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1105","doi-asserted-by":"crossref","DOI":"10.1002\/art.41041","article-title":"MicroRNA-125b regulates fibroblast apoptosis proliferation in systemic sclerosis","author":"Kozlova","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1110","first-page":"173","article-title":"Downregulation of miR-542-3p contributes to apoptosis resistance in dermal fibroblasts from systemic sclerosis patients via survivin overexpression","volume":"18","author":"Vahidi Manesh","year":"2019","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/exd.12900","article-title":"Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization","volume":"25","author":"Wang","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.semcdb.2019.12.007_bib1120","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2019.01100","article-title":"OTUD6B-AS1 might Be a novel regulator of apoptosis in systemic sclerosis","volume":"10","author":"Takata","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Seminars in Cell & Developmental Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952118302696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952118302696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:55:22Z","timestamp":1761065722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1084952118302696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":224,"alternative-id":["S1084952118302696"],"URL":"https:\/\/doi.org\/10.1016\/j.semcdb.2019.12.007","relation":{},"ISSN":["1084-9521"],"issn-type":[{"value":"1084-9521","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cell & Developmental Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcdb.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}